compounds that enhance autophagy have the potential to treat a wide range of neurodegenerative disease.
- MPL mechanism of action enhances autophagy.
- next week, we will know if this enhanced autophagy treats at least one neurodegenerative disease
- if yes, then the Professor says that it has the potential to treat a range of other neurodegenerative diseases.
That is, success next week, and value goes up by more that % success attributed to becoming SoC for MND/ALS ( 50% ? ).
You need to start throwing a % chance of success against other indications ( Alzheimer's Disease, Parkinson's etc. ), maybe 5%.
And that gets built into any offer for PAA.
Ann: PharmAust Forms World-Class Scientific Advisory Board, page-11
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $89.00M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.0¢ | 19.3¢ | $112.4K | 570.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 71364 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 457262 | 6 |
View Market Depth
| Last trade - 15.59pm 05/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |